Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11325801 | 0.84 | KMT2A (0.44) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL18281626 | 0.83 | KMT2A (0.61) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27487172 | 0.83 | KMT2A (0.43) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27502344 | 0.81 | KMT2A (0.42) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL4748576 | 0.80 | KMT2A (0.44) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL11492117 | 0.80 | CA2 (0.45) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL11778545 | 0.80 | KMT2A (0.48) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL28290788 | 0.78 | KMT2A (0.40) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27469362 | 0.77 | ALDH1A1 (0.52) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL11783974 | 0.77 | KMT2A (0.38) | KMT2ANPSR1SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221502-A1 | Anthrapyridone Compound and Salt Thereof, Magenta Ink Composition Containing the Anthrapyridone Compound, and Colored Article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-09-02 | — | — | US | claimed |
| US-7223301-B2 | Anthrapyridone compound, water-based magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-05-29 | — | — | US | claimed |
| US-20060219131-A1 | Anthrapyridone compound, aqueous magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-10-05 | — | — | US | claimed |
| EP-1626069-A1 | ANTHRAPYRIDONE COMPOUND, AQUEOUS MAGENTA INK COMPOSITION AND INKJET RECORDING METHOD | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-02-15 | — | — | EP | claimed |
| EP-0036838-B1 | AZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1984-09-26 | — | — | EP | claimed |
| US-4447357-A | Fibre-reactive azo dyestuffs containing a halotriazinyl radical and a non-reactive triazinyl radical | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | claimed |
| EP-0036838-A2 | Azo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1981-09-30 | — | — | EP | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-20100221502-A1 | Anthrapyridone Compound and Salt Thereof, Magenta Ink Composition Containing the Anthrapyridone Compound, and Colored Article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7223301-B2 | Anthrapyridone compound, water-based magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20060219131-A1 | Anthrapyridone compound, aqueous magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1626069-A1 | ANTHRAPYRIDONE COMPOUND, AQUEOUS MAGENTA INK COMPOSITION AND INKJET RECORDING METHOD | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-02-15 | — | — | EP | disclosed |
| EP-0036838-B1 | AZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1984-09-26 | — | — | EP | disclosed |
| US-4447357-A | Fibre-reactive azo dyestuffs containing a halotriazinyl radical and a non-reactive triazinyl radical | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0036838-A2 | Azo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1981-09-30 | — | — | EP | disclosed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4159984-A | METAL AND PROTON DONOR | SHIONOGI & CO., LTD. (JP) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221502-A1 | Anthrapyridone Compound and Salt Thereof, Magenta Ink Composition Containing the Anthrapyridone Compound, and Colored Article | ABL1, ATXN2L, ANXA7 | KMT2A 774/4885NPSR1 2390/4885SMN1; SMN2 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.